for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Beigene Ltd

6160.HK

Latest Trade

132.90HKD

Change

-4.20(-3.06%)

Volume

245,025

Today's Range

131.30

 - 

136.00

52 Week Range

130.30

 - 

278.60

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
137.10
Open
135.00
Volume
245,025
3M AVG Volume
14.39
Today's High
136.00
Today's Low
131.30
52 Week High
278.60
52 Week Low
130.30
Shares Out (MIL)
1,446.52
Market Cap (MIL)
200,100.30
Forward P/E
-18.69
Dividend (Yield %)
--

Next Event

Q4 2021 Beigene Ltd Earnings Release

Latest Developments

More

Beigene Announces Findings From Trial Of Tislelizumab Vs Placebo In Combination With Chemotherapy

The Capital Group Companies Inc's Long Position In BeiGene Rises To 8.03% - HKEX Filing

Beigene Says Co And Nanjing Leads Biolabs, Inc Announce Entry Into A License And Collaboration Agreement

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Beigene Ltd

Beigene Ltd is a biotechnology company in the commercial stage. The Company focuses on research and development (R&D), production and commercialization of innovative drugs. The Company has three products approved for listing, including Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317) and Pamiparib (BGB-290). The Company also has eight products in clinical stage, including BGB-283, BGB-A333, BGB-A425, BGB-A1217, BGB-A445, BGB-11417, BGB-10188 and BGB-15025. The Company's business covers China, the United States, Australia, Canada, Singapore, Russia, Brazil, Europe and other countries and regions.

Industry

Biotechnology & Drugs

Contact Info

Ke Xue Yuan Lu 30 Hao,Zhong Guan Cun

Sheng Ming Ke Xue Yuan, Chang Ping Qu

BEIJING, BEJ

China

http://www.beigene.cn/

Executive Leadership

John Victor Oyler

Co-Founder, Executive Chairman of the Board, Chief Executive Officer

Xiaobin Wu

President, Chief Operating Officer, General Manager - China

Xiaodong Wang

Co-Founder, Non-Executive Director

Julia Wang

Chief Financial Officer

Jane Huang

Chief Medical Officer, Hematology

Key Stats

1.92 mean rating - 13 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.2K

2019

0.4K

2020

0.3K

2021(E)

1.2K
EPS (USD)

2018

-0.930

2019

-1.220

2020

-1.470

2021(E)

-0.936
Price To Earnings (TTM)
--
Price To Sales (TTM)
24.19
Price To Book (MRQ)
6.36
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
19.16
LT Debt To Equity (MRQ)
5.98
Return on Investment (TTM)
-29.33
Return on Equity (TTM)
-24.03

Latest News

Latest News

Novartis options BeiGene anti-cancer therapy in $1 billion deal

Novartis has signed an option, collaboration and licence agreement with BeiGene Ltd for anti-cancer therapy ociperlimab (BGB-A1217) to expand its activities in immuno-oncology, the Swiss drugmaker said on Monday.

Biotech BeiGene slides in Shanghai after $3.5 billion STAR debut

Cancer treatment specialist BeiGene Ltd plunged 16.4% on its Shanghai debut on Wednesday after raising $3.5 billion, hit by concerns over its valuation amid potential U.S. sanctions on Chinese biotech companies.

Chinese biotech company BeiGene opens lower on Shanghai debut

Chinese biotech company BeiGene Ltd opened lower on its Shanghai debut on Wednesday after raising over $3 billion in the biggest STAR Market listing this year.

Beigene's cancer therapy meets late-stage study goal

Biotech firm Beigene Ltd, said on Friday its cancer therapy, tislelizumab, in combination with chemotherapy met the main goal of helping patients live longer by preventing the disease from progressing in a late-stage study.

UPDATE 1-Beigene's cancer therapy meets late-stage study goal

Biotech firm Beigene Ltd , said on Friday its cancer therapy, tislelizumab, in combination with chemotherapy met the main goal of helping patients live longer by preventing the disease from progressing in a late-stage study.

Amgen bets on $1.9-billion Five Prime deal to grow in Asia-Pacific oncology market

Drugmaker Amgen Inc is buying Five Prime Therapeutics for about $1.9 billion to expand its line of gastric cancer drug candidates and its presence in Asia-Pacific, the companies said on Thursday.

RPT-UPDATE 1-Novartis, once wary of Chinese M&A, dives into BeiGene's cancer immunotherapy

Swiss drugmaker Novartis paid $650 million to snag an immuno-oncology drug from BeiGene Ltd , the latest Western drugmaker turning to China for must-have assets to fill holes in their cancer portfolios.

Novartis, once wary of Chinese M&A, dives into BeiGene's cancer immunotherapy

Swiss drugmaker Novartis paid $650 million to snag an immuno-oncology drug from BeiGene Ltd, the latest Western drugmaker turning to China for must-have assets to fill holes in their cancer portfolios.

BeiGene, Novartis partner to develop cancer drug tislelizumab

China-based biotechnology company BeiGene Ltd said on Monday it will partner with Swiss firm Novartis AG to develop, manufacture and commercialize its cancer drug tislelizumab.

China's BeiGene to start human testing of COVID-19 antibody treatment in September

China-based drugmaker BeiGene Ltd said on Thursday that an early-stage human study to test its COVID-19 antibody treatment will begin in September.

BRIEF-Beigene Says Began Commercializing Xgeva (Denosumab) In China

* ON JUNE 30, CO BEGAN COMMERCIALIZING XGEVA (DENOSUMAB) IN CHINA FOR TREATMENT OF GIANT CELL TUMOR OF BONE Source text https://bit.ly/2ZpQivq Further company coverage:

BRIEF-BeiGene Announces Acceptance Of Supplemental New Drug Application For Tislelizumab

* BEIGENE ANNOUNCES ACCEPTANCE OF A SUPPLEMENTAL NEW DRUG APPLICATION FOR TISLELIZUMAB IN PATIENTS WITH PREVIOUSLY TREATED UNRESECTABLE HEPATOCELLULAR CARCINOMA IN CHINA Source text for Eikon: Further company coverage:

BRIEF-Beigene And Springworks Announce Presentation Of Preclinical Data From Solid Tumors Treatment

* BEIGENE AND SPRINGWORKS ANNOUNCE PRESENTATION OF PRECLINICAL DATA COMBINING RAF DIMER INHIBITOR LIFIRAFENIB WITH MEK INHIBITOR MIRDAMETINIB AND PROVIDE UPDATE ON ONGOING PHASE 1B/2 CLINICAL TRIAL

BRIEF-BeiGene Announces European Medicines Agency Acceptance Of Marketing Authorization Application For BRUKINSA

* BEIGENE ANNOUNCES EUROPEAN MEDICINES AGENCY ACCEPTANCE OF ITS MARKETING AUTHORIZATION APPLICATION FOR BRUKINSA® (ZANUBRUTINIB) FOR THE TREATMENT OF PATIENTS WITH WALDENSTRÖM’S MACROGLOBULINEMIA Source text for Eikon: Further company coverage:

BRIEF-Beigene Reports Approval Of Brukinsa In China For Small Lymphocytic Lymphoma

* BEIGENE ANNOUNCES THE APPROVAL OF BRUKINSA™ (ZANUBRUTINIB) IN CHINA FOR PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA AND RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA

BRIEF-Beigene Says Aspen Trial Did Not Achieve Statistical Significance On Its Primary Endpoint

* ASPEN TRIAL DID NOT ACHIEVE STATISTICAL SIGNIFICANCE ON ITS PRIMARY ENDPOINT Source text for Eikon: Further company coverage:

BRIEF-Beigene Presents Phase 3 Data On Tislelizumab Combined With Chemotherapy For The Treatment Of Patients With Advanced Squamous Non-Small Cell Lung Cancer

* BEIGENE PRESENTS PHASE 3 DATA ON TISLELIZUMAB COMBINED WITH CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH ADVANCED SQUAMOUS NON-SMALL CELL LUNG CANCER AT THE 2020 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) VIRTUAL SCIENTIFIC PROGRAM

BRIEF-Beigene Presents Updated Results From Phase 3 Trial Of Zanubrutinib vs Ibrutinib In Patients With Waldenström’S Macroglobulinemia

* BEIGENE PRESENTS UPDATED HEAD TO HEAD RESULTS FROM PHASE 3 TRIAL OF ZANUBRUTINIB VERSUS. IBRUTINIB IN PATIENTS WITH WALDENSTRÖM’S MACROGLOBULINEMIA AT THE 2020 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) VIRTUAL SCIENTIFIC PROGRAM Source text for Eikon: Further company...

BRIEF-Hutchison China MediTech Says Co, Beigene Enter Into Clinical Collaboration

* CHI-MED, BEIGENE ENTER INTO CLINICAL COLLABORATION TO EVALUATE COMBINATIONS OF SURUFATINIB, FRUQUINTINIB WITH TISLELIZUMAB

BRIEF-Beigene And Medison Pharma Announce Exclusive Distribution Agreement And Acceptance Of New Drug Application For Btk Inhibitor Brukinsa™ In Israel

* BEIGENE AND MEDISON PHARMA ANNOUNCE EXCLUSIVE DISTRIBUTION AGREEMENT AND ACCEPTANCE OF NEW DRUG APPLICATION FOR BTK INHIBITOR BRUKINSA™ (ZANUBRUTINIB) IN ISRAEL Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up